Colistin Use in Patients with Chronic Kidney Disease : Are We Underdosing Patients?

Home | About RECERCAT | Contact

Català | Castellano

All of RECERCAT

By Communities &
Collections By Defense Date By Authors By Titles By Subject

This Collection

By Defense Date By Authors By Titles By Subject

Statistics

View Statistics All RECERCAT

My RECERCAT

Other repositories directory

RECERCAT Home > Universitat Autònoma de Barcelona > Articles escrits per personal UAB o publicats per la universitat > View document

Title:	Colistin Use in Patients with Chronic Kidney Disease : Are We Underdosing Patients?
Author:	Sorlí, Luisa; Luque, Sonia; Li, Jian; Rodríguez García, Eva; Campillo, Nuria; Fernández-Sala, Xènia; Soldado, Jade; Domingo, Ignacio; Montero, Milagro; Grau, Santiago; Horcajada, Juan Pablo.; Universitat Autònoma de Barcelona
Abstract:	Colistin is administered as its inactive prodrug colistimethate (CMS). Selection of an individualized CMS dose for each patient is difficult due to its narrow therapeutic window, especially in patients with chronic kidney disease (CKD). Our aim was to analyze CMS use in patients with CKD. Secondary objectives were to assess the safety and efficacy of CMS in this special population. In this prospective observational cohort study of CMS-treated CKD patients, CKD was defined as the presence of a glomerular filtration rate (GFR) < 60 mL/min/m 2 for more than 3 months. The administered doses of CMS were compared with those recently published in the literature. Worsened CKD at the end of treatment (EOT) was evaluated with the RIFLE (Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease) criteria. Colistin plasma concentrations (C) were measured using high-performance liquid chromatography. Fifty-nine patients were included. Thirty-six (61.2%) were male. The median age was 76 (45-95) years and baseline GFR was 36.6 ± 13.6. The daily mean CMS dosage used was compared with recently recommended doses (3.36 vs. 6.07; p < 0.001). Mean C was 0.9 (0.2-2.9) mg/L, and C was <2 mg/L in 50 patients (83.3%). Clinical cure was achieved in 43 (72.9%) patients. Worsened renal function at EOT was present in 20 (33.9%) patients and was reversible in 10 (52.6%). The CMS dosages used in this cohort were almost half those currently recommended. The mean achieved C were under the recommended target of 2 mg/dL. Despite this, clinical cure rate was high. In this patient cohort, the incidence of nephrotoxicity was similar to those found in other recent studies performed in the general population and was reversible in 52.6%. These results suggest that CMS is safe and effective in patients with CKD and may encourage physicians to adjust dosage regimens to recent recommendations in order to optimize CMS treatments.
Subject(s):	-Colistin -Colistin plasma concentrations -Chronic kidney disease -Pharmacokinetic -Toxicodynamic
Rights:	open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/
Document type:	Article
Published by:
Share:
Uri:	https://ddd.uab.cat/record/226335

Show full item record

All of RECERCAT

This Collection

Statistics

My RECERCAT

Related documents

Other documents of the same author